Egetis Therapeutics Ab · OMXSTO:EGTX
Egetis Therapeutics Ab — Q2 2026 Earnings Presentation
13 slides from Egetis Therapeutics Ab's earnings presentation, Aug 21, 2026
Slide 1: We Care for the Rare – Webcast Quarter 2 2026 Report
WE CARE FOR THE RARE Webcast - Quarter 2 2026 Report August 21, 2026 Egetis Therapeutics For analysts and investors ©2026 Egetis Therapeutics. All rights reserved.
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. IMPORTANT: You must read the
Slide 3: Agenda for today
Agenda for today ➢ Business update Nicklas Westerholm, CEO ➢ Launch preparations in U.S. Anny Bedard, President, Egetis North America ➢ Commercialization update in EU and Henrik Krook, VP Commercial Operations other international markets ➢ Financial update Yilmaz Mahshid, CFO ➢ Looking ahead Nicklas
Slide 4: Business update
Business update FDA’s review of Emcitate® NDA progressing according to plan towards September 28, 2026, PDUFA action date ▪ Emcitate® launch in the U.S. planned for Q4 2026, subject to approval ▪ Egetis granted MCT8 deficiency composition patent in the U.S. ▪ Q2 revenue MSEK 17.4, +23% (CER) vs Q2 2
Slide 5: Launch preparations in US and commercialization in EU
Launch preparations in US and commercialization in EU Q2-2026 5
Slide 6: The Team is Built and Launch Infrastructure is Being Activated
The Team is Built and Launch Infrastructure is Being Activated Patient support program Market access Patient support capabilities and operating model Payer strategy, value communication, and account established coverage in place Experienced Team Ready for Launch • Core commercial team hiring Distrib
Slide 7: Continuity of Care for EAP Patients is Our Top Priority
Continuity of Care for EAP Patients is Our Top Priority Tiratricol EAP continuity of care — ensuring Patient-level transition planning uninterrupted treatment Confirm the pathway and treating physician for each EAP patient at approval Enrollment & prescriber readiness A coordinated transition from e
Slide 8: Europe & International
Europe & International Q2 revenue MSEK 17.4, +23% (CER) vs Q2 2025 and +30% vs Q1 2026; momentum building on German reimbursement conclusion and broader geographic reach Germany • Price negotiations with GKV-Spitzenverband concluded in Q2 2026 • Continued disease awareness, physician engagement and
Slide 9: Financials
Financials Q2-2026 9
Slide 10: Financial Overview – Second Quarter
Financial Overview – Second Quarter • Total revenue ‒ Q2-2026 of 17.4 MSEK vs. 14.5 MSEK for Q2-2025, +23% YoY CER. • Cost of goods sold impacted by intangible R&D depreciation ‒ During Q2-2026 R&D depreciation of 10.1 MSEK is included in COGS ‒ Excluding the depreciation Gross profit would have bee
Slide 11: Looking ahead
Looking ahead 11
Slide 12: Emcitate (tiratricol) U.S. Launch in 2026 and indication expansion opportunity
Emcitate® (tiratricol) U.S. Launch in 2026 and indication expansion opportunity Upcoming key milestones • PDUFA date September 28 • Priority Review Voucher (upon approval) • Expected launch of Emcitate® (tiratricol) in the U.S. (Q4) • Finalize the development plan for Emcitate in RTH-beta ©2026 Eget
Slide 13: Thank you!
Thank you! Egetis Therapeutics egetis.com 13